We are a kids-first, clinical-stage biotechnology company focused on harnessing the power of CAR-T cell technology for tumors n the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology to adult indications. We are building a platform to optimize the application of CAR-T technology in CNS tumors-- prioritizing diffuse intrinsic pontine glioma (DIPG) with plans to expand to other pediatric and adult brain tumors, including brain metastases.
| Website | http://www.brainchildbio.com |
| Revenue | $6.8 million |
| Employees | 58 (46 on RocketReach) |
| Phone | +1 206-677-8359 |
| Industry | Biotechnology Research |
| Keywords | Pediatric Oncology, Cancer Immunotherapy, Biotechnology, Clinical Trials, Cell Therapy, Oncology, Immunotherapy, Drug Development, Children's Cancer, Cancer Research, Biopharmaceutical, Clinical Stage, Tumor Treatment, Cancer Treatment, Cell Therapy Research |
| Competitors | Illumina, Thermo Fisher Scientific, Roche, Agilent Technologies, Bio-Rad Laboratories, QIAGEN, Promega Corporation, Bioneer, DNA Script +39 more (view full list) |
Looking for a particular BrainChild Bio employee's phone or email?
BrainChild Bio Questions
The BrainChild Bio annual revenue was $6.8 million in 2026.
Joshua Gustafson is the Vice President, Research And Development of BrainChild Bio.
46 people are employed at BrainChild Bio.
Top BrainChild Bio Employees
-
22
-
25+
-
David Slatcher
Senior VP, Head of Finance at BrainChild Bio
Boston, MA, US25+ -
35
-
Chithkala Harinarayan
Vice President, Quality at BrainChild Bio
Atlanta, GA, US21 -
Rich Getto
Senior Vice President at BrainChild Bio
Seattle, WA, US33 -
Jessica Hussell
Senior Director, Program Lead at BrainChild Bio
Kirkland, WA, US25+ -
22
-
Dan Miskimin
Director of MSAT at BrainChild Bio
Seattle, WA, US24
